The activation of the JAK/STAT and NF-κB signaling pathways is considered to be a characteristic of EBV-positive diffuse large B-cell lymphoma (DLBCL) patients, while the expression of JAK/STAT and NF-κB signaling is not obvious in EBV-negative DLBCL patients [37]. Here, NFKB1 is linked to diffuse large B-cell lymphoma.